These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 30207015)

  • 1. A typology of prescription drug monitoring programs: a latent transition analysis of the evolution of programs from 1999 to 2016.
    Smith N; Martins SS; Kim J; Rivera-Aguirre A; Fink DS; Castillo-Carniglia A; Henry SG; Mooney SJ; Marshall BDL; Davis C; Cerdá M
    Addiction; 2019 Feb; 114(2):248-258. PubMed ID: 30207015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prescription drug monitoring programs operational characteristics and fatal heroin poisoning.
    Martins SS; Ponicki W; Smith N; Rivera-Aguirre A; Davis CS; Fink DS; Castillo-Carniglia A; Henry SG; Marshall BDL; Gruenewald P; Cerdá M
    Int J Drug Policy; 2019 Dec; 74():174-180. PubMed ID: 31627159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring Relationships Between Proactive Reporting State-level Prescription Drug Monitoring Programs and County-level Fatal Prescription Opioid Overdoses.
    Cerdá M; Ponicki WR; Smith N; Rivera-Aguirre A; Davis CS; Marshall BDL; Fink DS; Henry SG; Castillo-Carniglia A; Wintemute GJ; Gaidus A; Gruenewald PJ; Martins SS
    Epidemiology; 2020 Jan; 31(1):32-42. PubMed ID: 31596794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescription drug monitoring programs and drug overdose deaths involving benzodiazepines and prescription opioids.
    Liang D; Shi Y
    Drug Alcohol Rev; 2019 Jul; 38(5):494-502. PubMed ID: 31317593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescription drug monitoring program design and function: A qualitative analysis.
    Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC
    Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Features of prescription drug monitoring programs associated with reduced rates of prescription opioid-related poisonings.
    Pauly NJ; Slavova S; Delcher C; Freeman PR; Talbert J
    Drug Alcohol Depend; 2018 Mar; 184():26-32. PubMed ID: 29402676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mandatory Review of Prescription Drug Monitoring Program Before Issuance of a Controlled Substance Results in Overall Reduction of Prescriptions Including Opioids and Benzodiazepines.
    Manders L; Abd-Elsayed A
    Pain Physician; 2020 Jun; 23(3):299-304. PubMed ID: 32517396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
    Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
    MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States.
    Moyo P; Simoni-Wastila L; Griffin BA; Onukwugha E; Harrington D; Alexander GC; Palumbo F
    Addiction; 2017 Oct; 112(10):1784-1796. PubMed ID: 28498498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
    Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
    Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Opioid Prescribing Behaviors - Prescription Behavior Surveillance System, 11 States, 2010-2016.
    Strickler GK; Kreiner PW; Halpin JF; Doyle E; Paulozzi LJ
    MMWR Surveill Summ; 2020 Jan; 69(1):1-14. PubMed ID: 31999681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of New York prescription drug monitoring program, I-STOP, on statewide overdose morbidity.
    Brown R; Riley MR; Ulrich L; Kraly EP; Jenkins P; Krupa NL; Gadomski A
    Drug Alcohol Depend; 2017 Sep; 178():348-354. PubMed ID: 28692945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers.
    Deyo RA; Hallvik SE; Hildebran C; Marino M; Springer R; Irvine JM; O'Kane N; Van Otterloo J; Wright DA; Leichtling G; Millet LM; Carson J; Wakeland W; McCarty D
    J Pain; 2018 Feb; 19(2):166-177. PubMed ID: 29054493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
    Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
    Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of state prescription drug monitoring programs: a state-by-state survey.
    Manasco AT; Griggs C; Leeds R; Langlois BK; Breaud AH; Mitchell PM; Weiner SG
    Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):847-51. PubMed ID: 27061342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impacts of prescription drug monitoring program policy changes and county opioid safety coalitions on prescribing and overdose outcomes in California, 2015-2018.
    Henry SG; Shev AB; Crow D; Stewart SL; Wintemute GJ; Fenlon C; Wirtz SJ
    Prev Med; 2021 Dec; 153():106861. PubMed ID: 34687731
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in opioid and other analgesic prescribing following voluntary and mandatory prescription drug monitoring program implementation: A time series analysis of early outcomes.
    Nielsen S; Picco L; Russell G; Pearce C; Andrew NE; Lubman DI; Bell JS; Buchbinder R; Xia T
    Int J Drug Policy; 2023 Jul; 117():104053. PubMed ID: 37209441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician attitudes and experiences with Maryland's prescription drug monitoring program (PDMP).
    Lin DH; Lucas E; Murimi IB; Jackson K; Baier M; Frattaroli S; Gielen AC; Moyo P; Simoni-Wastila L; Alexander GC
    Addiction; 2017 Feb; 112(2):311-319. PubMed ID: 27658522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance of a Predictive Model versus Prescription-Based Thresholds in Identifying Patients at Risk of Fatal Opioid Overdose.
    Ferris LM; Saloner B; Jackson K; Lyons BC; Murthy V; Kharrazi H; Latimore A; Stuart EA; Weiner JP
    Subst Use Misuse; 2021; 56(3):396-403. PubMed ID: 33446000
    [No Abstract]   [Full Text] [Related]  

  • 20. Protocol: mixed-methods study to evaluate implementation, enforcement, and outcomes of U.S. state laws intended to curb high-risk opioid prescribing.
    McGinty EE; Stuart EA; Caleb Alexander G; Barry CL; Bicket MC; Rutkow L
    Implement Sci; 2018 Feb; 13(1):37. PubMed ID: 29482599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.